Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.92 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.59 |
| ▸ | ARG2 | P78540 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eflornithine SCHEMBL4510 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL3238104 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL559145 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4809264 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2023-09-21 | — | — | US | disclosed |
| EP-3831839-A2 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | ViiV Healthcare UK (No.5) Limited (GB) | 2021-06-09 | — | — | EP | disclosed |
| EP-3411381-B1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3750910-A1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV Healthcare UK(No.4) Limited (GB) | 2020-12-16 | — | — | EP | disclosed |
| EP-3478662-B1 | AZADECALIN DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO5) LTD (GB) | 2020-09-16 | — | — | EP | disclosed |
| EP-3129392-B1 | TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY, SUBSTITUTED IN POSITION 3 BY A NON-AROMATIC RING CARRYING A HALOALKYL SUBSTITUENT | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-08-05 | — | — | EP | disclosed |
| EP-3286166-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| EP-3334723-B1 | 5-(N-[6,5]-FUSED BICYCLIC ARYL TETRAHYDROISOQUINOLIN-6-YL) PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2019-09-18 | — | — | EP | disclosed |
| EP-2205283-B1 | CHOLESTEROL CONJUGATES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA SRL (IT) | 2019-03-20 | — | — | EP | disclosed |
| EP-1467970-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1430058-A1 | SODIUM SALT OF AN HIV INTEGRASE INHIBITOR | Merck & Co., Inc. (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003077857-A2 | N-(SUBSTITUTED BENZYL)-8-HYDROXY-1,6-NAPHTHYRIDINE-7- CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003062204-A1 | HYDROXYNAPHTHYRIDINONE CARBOXAMIDES USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003016315-A1 | SODIUM SALT OF AN HIV INTEGRASE INHIBITOR | MERCK & CO., INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002096359-A2 | PIPERAZINE PENTANAMIDE HIV PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-0734387-B1 | HIV PROTEASE INHIBITORS | MERCK & CO INC (US) | 2002-04-10 | — | — | EP | disclosed |
| CN-1344270-A | Functionalized heterocycles as chemokine receptor modulators | THOUSAND YEARS MEDICAMENTS INC (US) | 2002-04-10 | — | — | CN | disclosed |
| US-6316449-B1 | Chemokine receptor antagonists | MILLENNIUM PHARMACEUTICALS, INC. | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295220-A1 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | IL17A, BET1, CD4 | ODC1 2053/4885BLM 4418/4885LMNA 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.